Dabur India Receives US FDA Warning for Silvassa Facility Data Integrity
Dabur India received a warning letter from the US FDA over manufacturing issues at its Silvassa facility, citing concerns on data integrity, CGMP compliance, quality systems, and data management during a regulatory inspection. The company said Indian operations and products sold in India are unaffected and reported corrective actions including data integrity training, independent oversight, and gap closures. The update follows recent scrutiny from another regulator over “100% natural” and “100% pure” product claims.